Proton pump inhibitors induced fungal dysbiosis in patients with gastroesophageal reflux disease

被引:5
|
作者
Shi, Yichao [1 ,2 ]
Li, Jianfeng [2 ]
Cai, Shuntian [2 ]
Zhao, Hong [3 ]
Zhao, Huijun [2 ]
Sun, Gang [2 ]
Yang, Yunsheng [2 ,4 ]
机构
[1] Peking Univ, Aerosp Ctr Hosp, Dept Gastroenterol, Aerosp Sch Clin Med, Beijing, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Gastroenterol & Hepatol, Beijing, Peoples R China
[3] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 1, Dept Neurol, Beijing, Peoples R China
[4] Chinese Peoples Liberat Army Gen Hosp, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China
关键词
gastroesophageal reflux disease; proton pump inhibitor; fecal mycobiota; Candida; gastric mucosal mycobiota; LONG-TERM USE; CANDIDA-ALBICANS; COMMENSAL FUNGI; THERAPY; MICROBIOME; RISK; INFLAMMATION; PROPHYLAXIS; MEDICATION; ESOPHAGUS;
D O I
10.3389/fcimb.2023.1205348
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Gut mycobiota inhabits human gastrointestinal lumen and plays a role in human health and disease. We investigated the influence of proton pump inhibitors (PPIs) on gastric mucosal and fecal mycobiota in patients with gastroesophageal reflux diseases (GERD) by using Internal Transcribed Spacer 1 sequencing. A total of 65 participants were included, consisting of the healthy control (HC) group, GERD patients who did not use PPIs (nt-GERD), and GERD patients who used PPIs, which were further divided into short-term (s-PPI) and long-term PPI user (l-PPI) groups based on the duration of PPI use. The alpha diversity and beta diversity of gastric mucosal mycobiota in GERD patients with PPI use were significantly different from HCs, but there were no differences between s-PPI and l-PPI groups. LEfSe analysis identified Candida at the genus level as a biomarker for the s-PPI group when compared to the nt-GERD group. Meanwhile, Candida, Nothojafnea, Rhizodermea, Ambispora, and Saccharicola were more abundant in the l-PPI group than in the nt-GERD group. Furthermore, colonization of Candida in gastric mucosa was significantly increased after PPI treatment. However, there was no significant difference in Candida colonization between patients with endoscopic esophageal mucosal breaks and those without. There were significant differences in the fecal mycobiota composition between HCs and GERD patients regardless whether or not they used PPI. As compared to nt-GERD patient samples, there was a high abundance of Alternaria, Aspergillus, Mycenella, Exserohilum, and Clitopilus in the s-PPI group. In addition, there was a significantly higher abundance of Alternaria, Aspergillus, Podospora, Phallus, and Monographella in the l-PPI group than nt-GERD patients. In conclusion, our study indicates that dysbiosis of mycobiota was presented in GERD patients in both gastric mucosal and fecal mycobiota. PPI treatment may increase the colonization of Candida in the gastric mucosa in GERD patients.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Prevalence of bile reflux in gastroesophageal reflux disease patients not responsive to proton pump inhibitors
    Luigi Monaco
    Antonio Brillantino
    Francesco Torelli
    Michele Schettino
    Giuseppe Izzo
    Angelo Cosenza
    Natale Di Martino
    World Journal of Gastroenterology, 2009, 15 (03) : 334 - 338
  • [2] Prevalence of bile reflux in gastroesophageal reflux disease patients not responsive to proton pump inhibitors
    Monaco, Luigi
    Brillantino, Antonio
    Torelli, Francesco
    Schettino, Michele
    Izzo, Giuseppe
    Cosenza, Angelo
    Di Martino, Natale
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (03) : 334 - 338
  • [3] Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe
    Gyawali C.P.
    Current Gastroenterology Reports, 2017, 19 (9)
  • [4] Gastroesophageal reflux disease and asthma - The role of proton pump inhibitors
    Menon, MS
    Al-Hajji, M
    Morice, A
    CHEST, 2006, 129 (06) : 1732 - 1732
  • [5] The evolution of proton pump inhibitors for the treatment of gastroesophageal reflux disease
    Friedlander, Elizabeth A.
    Pallentino, Julia
    Miller, Sally K.
    VanBeuge, Susan S.
    JOURNAL OF THE AMERICAN ACADEMY OF NURSE PRACTITIONERS, 2010, 22 (12): : 674 - 683
  • [6] Helicobacter pylori, proton pump inhibitors and gastroesophageal reflux disease
    Kuipers, EJ
    Klinkenberg-Knol, EC
    Meuwissen, SGM
    YALE JOURNAL OF BIOLOGY AND MEDICINE, 1999, 72 (2-3): : 211 - 218
  • [8] PROTON PUMP INHIBITORS IN THE TREATMENT OF ACUTE GASTROESOPHAGEAL REFLUX DISEASE
    WOROBETZ, LJ
    CANADIAN JOURNAL OF GASTROENTEROLOGY, 1993, 7 (05): : 417 - 421
  • [9] (IN)APPROPRIATE USE OF PROTON PUMP INHIBITORS IN GASTROESOPHAGEAL REFLUX DISEASE
    Elkhouly, Mohamed
    Kotwal, Vikram
    Attar, Bashar M.
    Trick, William
    Diep, Lisa
    GASTROENTEROLOGY, 2018, 154 (06) : S239 - S239
  • [10] Gastroesophageal Reflux Treatment With Proton Pump Inhibitors in Patients With Hypertension
    Sertorio, Jonas T. C.
    Tanus-santos, Jose E.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2019, 53 (02) : 157 - 158